Amarin Corp PLC (AMRN)
0.8717
-0.01
(-1.08%)
USD |
NASDAQ |
Apr 19, 16:00
0.8717
0.00 (0.00%)
After-Hours: 20:00
Amarin Enterprise Value: 33.01M for April 18, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 18, 2024 | 33.01M |
| April 17, 2024 | 47.42M |
| April 16, 2024 | 38.91M |
| April 15, 2024 | 48.03M |
| April 12, 2024 | 63.44M |
| April 11, 2024 | 88.72M |
| April 10, 2024 | 96.75M |
| April 09, 2024 | 104.78M |
| April 08, 2024 | 108.79M |
| April 05, 2024 | 100.76M |
| April 04, 2024 | 104.78M |
| April 03, 2024 | 104.78M |
| April 02, 2024 | 76.68M |
| April 01, 2024 | 33.34M |
| March 28, 2024 | 36.87M |
| March 27, 2024 | 36.23M |
| March 26, 2024 | 26.91M |
| March 25, 2024 | 18.04M |
| March 22, 2024 | 24.39M |
| March 21, 2024 | 25.11M |
| March 20, 2024 | 39.36M |
| March 19, 2024 | 27.52M |
| March 18, 2024 | 15.27M |
| March 15, 2024 | 24.06M |
| March 14, 2024 | 9.214M |
| Date | Value |
|---|---|
| March 13, 2024 | 25.71M |
| March 12, 2024 | 26.31M |
| March 11, 2024 | 38.87M |
| March 08, 2024 | 49.83M |
| March 07, 2024 | 51.40M |
| March 06, 2024 | 60.31M |
| March 05, 2024 | 57.06M |
| March 04, 2024 | 50.19M |
| March 01, 2024 | 104.78M |
| February 29, 2024 | 108.79M |
| February 28, 2024 | 209.13M |
| February 27, 2024 | 221.17M |
| February 26, 2024 | 164.98M |
| February 23, 2024 | 156.95M |
| February 22, 2024 | 163.93M |
| February 21, 2024 | 157.77M |
| February 20, 2024 | 168.04M |
| February 16, 2024 | 174.02M |
| February 15, 2024 | 178.11M |
| February 14, 2024 | 161.75M |
| February 13, 2024 | 141.31M |
| February 12, 2024 | 174.02M |
| February 09, 2024 | 178.11M |
| February 08, 2024 | 182.19M |
| February 07, 2024 | 169.93M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-51.19M
Minimum
Nov 02 2023
8.066B
Maximum
Dec 13 2019
1.819B
Average
1.106B
Median
Enterprise Value Benchmarks
| Trinity Biotech PLC | 120.06M |
| DBV Technologies SA | -13.34M |
| Adaptimmune Therapeutics PLC | 74.81M |
| Akari Therapeutics PLC | 5.743M |
| Biodexa Pharmaceuticals Plc | -- |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.781M |
| Revenue (Quarterly) | 74.71M |
| Total Expenses (Quarterly) | 79.32M |
| EPS Diluted (Quarterly) | -0.02 |
| Gross Profit Margin (Quarterly) | 60.40% |
| Profit Margin (Quarterly) | -7.74% |
| Earnings Yield | -17.21% |
| Normalized Earnings Yield | -14.23 |